Oncology & Cancer

Tailoring lung cancer therapies to individual patients

Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.

Oncology & Cancer

Researchers develop new generation tumor-specific pro-IL-12

Interleukin-12 (IL-12), a potent inducer of cell-mediated immunity, can stimulate the anti-tumor effector functions of the activated T and NK cells for solid tumors rejection. However, clinical administration of IL-12 has ...

Diseases, Conditions, Syndromes

Treatments explored for moderate-to-severe alopecia areata

(HealthDay)—For patients with alopecia areata (AA), treatment with an inhibitor of janus kinase (JAK)3 and the tyrosine kinase expressed in the hepatocellular carcinoma kinase family, ritlecitinib, and an inhibitor of tyrosine ...

Neuroscience

Findings reveal new mechanism of activation for ALK

ALK is a receptor tyrosine kinase that regulates important functions in the central nervous system. Scientists at St. Jude Children's Research Hospital have used leading-edge structural biology techniques to reveal in more ...

Oncology & Cancer

Decreasing DNA repair and genomic instability

The journal Oncotarget has published "Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal ...

page 1 from 24